Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesMyeloproliferative Diseases and Disorders, Poorly Differentiated NeoplasmsDRG 845-other-myeloproliferative-disorders-or-poorly-differentiated-neoplastic-diagnoses-without-cc-mcc
    Ask Trek AI about this page

    Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses: Inpatient Reimbursement Overview

    DRG 845 addresses inpatient stays for other myeloproliferative disorders or poorly differentiated neoplastic diagnoses without Complication or Comorbidity or Major Complication or Comorbidity. It defines the clinical scope and relative resource use used to determine Medicare inpatient reimbursement for lower-acuity hematology and oncology admissions.

    Customize your policy alerts

    Sign up for drg 845 policy alerts

    Get alerted when payer policies referencing 845 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 845 Overview

    DRG 845 covers hospital inpatient admissions for patients with other myeloproliferative disorders or poorly differentiated neoplastic diagnoses without a Complication or Comorbidity or a Major Complication or Comorbidity. Clinically this includes primary hematologic proliferative disorders and cases where definitive neoplastic classification is not established during the stay. This Diagnosis-Related Group matters for Medicare payment because it assigns a base payment relative to the expected resources for these less complex hematology oncology admissions. Accurate coding and documentation of diagnosis specificity and comorbid conditions affect grouping and reimbursement.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Trials evaluating novel targeted therapies or immunomodulatory agents for poorly differentiated hematologic malignancies presenting without major complications: these studies enroll hospitalized adults diagnosed with atypical myeloproliferative disorders or poorly differentiated neoplastic hematologic conditions who do not have CC/MCC-level complications, testing efficacy and safety of new molecularly targeted or immune-based agents compared with standard of care. Research objectives include measuring short-term hematologic response rates, toxicity profiles in the inpatient setting, and biomarkers predictive of response; findings inform inpatient treatment pathways and expected resource utilization relevant to payers.
    • Comparative effectiveness studies of inpatient vs. early outpatient management strategies for stabilization and initiation of therapy in myeloproliferative disorders: pragmatic trials or observational cohort studies assess outcomes for patients admitted for symptomatic cytoses, anemia, or constitutional symptoms who are randomized or propensity-matched to receive initial stabilization and therapy during hospitalization versus expedited outpatient initiation with close follow-up. These studies target cost, readmission rates, complication incidence, and quality-of-life endpoints, providing evidence on optimal site-of-care decisions that directly affect hospital reimbursements and care coordination costs.
    • Post-discharge outcomes and health services research focusing on readmission risk stratification and transitional care interventions for this population: cohort studies and interventional trials evaluate discharge planning models, outpatient monitoring intensity, and supportive-care pathways for patients discharged after treatment initiation or stabilization for other myeloproliferative disorders or poorly differentiated neoplasms. By identifying predictors of 30- and 90-day readmissions, adverse events, and outpatient resource use, this research helps providers develop risk-adjusted care pathways and helps payers design case management and bundled-payment strategies aligned with real-world outcomes.

    Related Codes

    820-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Lymphoma and Leukemia with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    821-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Lymphoma and Leukemia with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    822-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

    823-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-MCC

    Lymphoma and Non-Acute Leukemia with Other Procedures with MCC: Inpatient Reimbursement Overview

    824-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-CC

    Lymphoma and Non-Acute Leukemia with Other Procedures with CC: Inpatient Reimbursement Overview

    825-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC: Inpatient Reimbursement Overview

    826-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    827-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    828-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    829-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-OTHER-PROCEDURES-WITH-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    Showing 1–10 of 27

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.